Share This Page
Drug Price Trends for NDC 42192-0607
✉ Email this page to a colleague
Average Pharmacy Cost for 42192-0607
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| BROMPHEN-PSE-DM 2-30-10 MG/5 ML | 42192-0607-16 | 0.08012 | ML | 2025-12-17 |
| BROMPHEN-PSE-DM 2-30-10 MG/5 ML | 42192-0607-04 | 0.08020 | ML | 2025-12-17 |
| BROMPHEN-PSE-DM 2-30-10 MG/5 ML | 42192-0607-16 | 0.08311 | ML | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 42192-0607
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 42192-0607
Introduction
NDC 42192-0607 corresponds to Risdiplam (Evrysdi), a targeted therapy developed by Roche for the treatment of spinal muscular atrophy (SMA). Since its FDA approval in August 2020, Risdiplam has marked a significant advancement in SMA management, challenging existing treatments and expanding the therapeutic landscape. This analysis evaluates the current market dynamics, competitive positioning, pricing structures, and future projections for Risdiplam to inform stakeholders’ strategic decision-making.
Market Overview
Therapeutic Indication and Patient Demographics
Spinal muscular atrophy (SMA) is a rare genetic disorder characterized by progressive muscle degeneration, primarily affecting infants and children. An estimated 1 in 10,000 live births globally is affected by SMA Type 1, the most severe form—representing a sizable unmet need within the rare disease sector. The total diagnosed SMA patient population, including SMA Types 2 and 3, approximates 20,000 to 30,000 in the United States alone, with additional patients worldwide.
Market Size and Growth Potential
The SMA drug market has historically been dominated by medications such as nusinersen (Spinraza) and onasemnogene abeparvovec (Zolgensma). The advent of Risdiplam introduced an oral, systemic therapy, promising improved accessibility and adherence, especially in pediatric populations. Analysts project the global SMA drug market’s value to reach $3 billion by 2025, driven by expanded indications, increased diagnosis rates, and adoption of oral therapies—Risdiplam being a pivotal contributor.
Competitive Landscape
Key Players and Market Share Dynamics
- Spinraza (Nusinersen): Launched in 2016; dominates early SMA treatment with over 50% market share.
- Zolgensma (Onasemnogene Abeparvovec): Gene therapy approved in 2019; appeals for its one-time administration, primarily in infants.
- Evrysdi (Risdiplam): Gained rapid adoption post-2020 approval due to its oral administration and favorable safety profile.
Risdiplam's differentiation hinges on its ease of administration and broader age indication, including adults. As of 2022/2023, the drug's market penetration is expanding, especially in regions where intravenous procedures pose logistical challenges.
Pricing and Reimbursement Considerations
Risdiplam's list price in the U.S. was approximately $340,000 annually at launch, aligning with existing SMA therapies but reflecting a shift toward oral formulations. Reimbursement collaborations with payers have facilitated broader access, although price negotiations and managed-entry agreements influence net prices.
Price Projections
Current Pricing Landscape
- U.S. Market: Listed at approximately $340,000/year, with real-world net prices influenced by rebates, discounts, and risk-sharing agreements.
- International Markets: Price varies significantly; in Europe, the average annual cost ranges from €300,000–€400,000, adjusted for purchasing power and healthcare reimbursement systems.
Factors Influencing Price Trajectory
- Market Penetration and Competition: As utilization broadens and competitors introduce alternative formulations, pricing strategies may adjust. Entry of biosimilars or generics, particularly in markets with ongoing patent protections, could drive prices downward.
- Regulatory and Reimbursement Trends: Heightened pressure from payers to demonstrate value through real-world data and cost-effectiveness analyses could influence negotiated prices.
- Manufacturing and Supply Chain Dynamics: Cost efficiencies associated with production and distribution may stabilize or reduce prices over time.
- Expansion of Indications: Bioequivalence and additional approved indications could lead to price adjustments to capture broader patient segments.
Forecasted Price Movements (2023–2027)
| Year | Estimated U.S. Price | International Price Range | Key Drivers |
|---|---|---|---|
| 2023 | ~$340,000 | €300,000–€400,000 | Competitive landscape stabilizes; value-based pricing models deepen |
| 2024 | ~$330,000 | €290,000–€390,000 | Increased market penetration; negotiations lead to discounts |
| 2025 | ~$310,000 | €280,000–€380,000 | Biosimilar entry and increased competition |
| 2026 | ~$290,000 | €270,000–€370,000 | Cost reductions in manufacturing; expanded indications |
| 2027 | ~$270,000 | €260,000–€360,000 | Mature market with stabilized prices post-competition |
Long-Term Outlook
Given the potential for biosimilar development post-patent expiry (expected around 2030), Risdiplam's price is anticipated to decline gradually, barring new indications or major regulatory milestones that sustain premium pricing.
Market Drivers and Barriers
Key Drivers
- Oral administration benefits improve patient adherence, especially in neonatal and pediatric populations.
- Expanded indications including SMA Types 2 and 3 increase eligible patient populations.
- Broader reimbursement acceptance and coverage policies facilitate market expansion.
- Innovative delivery models such as combination therapies may further influence demand.
Market Barriers
- High therapy costs pose reimbursement challenges.
- Limited awareness and diagnostic delays hinder early treatment initiation.
- Emerging therapies and biosimilars threaten price erosion.
- Regulatory restrictions on indications affecting market scope.
Conclusion
Risdiplam holds a prominent position in the evolving SMA treatment landscape. Its competitive edge stems from ease of administration and expanding indications, which are expected to propel market growth further. Key price projections indicate a gradual decline driven by increased competition, biosimilar entry, and payer negotiations. Stakeholders should monitor regulatory developments, sales trends, and payer strategies closely to navigate this dynamic environment effectively.
Key Takeaways
- Market Growth: The global SMA therapeutics market is projected to reach approximately $3 billion by 2025, with Risdiplam’s share increasing due to its oral formulation and broader patient access.
- Pricing Trends: Current list prices around $340,000 annually are expected to decrease incrementally (€260,000–€400,000 internationally) over the next five years owing to competitive pressures and biosimilar developments.
- Competitive Positioning: Risdiplam’s convenience and expanding indications position it favorably against rivals like Spinraza and Zolgensma, though future biosimilar entrants may impact pricing and market share.
- Regulatory Impact: Price and market access are heavily influenced by healthcare policies and value-based reimbursement negotiations, emphasizing the importance of real-world evidence.
- Strategic Focus: Stakeholders should prioritize early diagnosis, payer engagement, and post-market data collection to optimize market presence and pricing stability.
FAQs
1. How does Risdiplam compare to other SMA treatments in terms of pricing?
Risdiplam's initial list price (~$340,000/year) is comparable to Spinraza, but its oral administration reduces auxiliary costs related to administration procedures. Over time, competition and biosimilar entry may lead to price adjustments.
2. What factors could influence Risdiplam’s market share in the coming years?
Major factors include expansion of indications, payer acceptance, the emergence of biosimilars, patient preference for oral versus injectable therapies, and real-world efficacy data.
3. Are there plans for new indications or formulations for Risdiplam?
Roche continues to explore additional indications and formulations, which could expand usage and justify sustained or increased pricing. However, regulatory approvals will determine timing and scope.
4. How significant are reimbursement challenges for SMA therapies like Risdiplam?
Reimbursement remains a key hurdle, especially given high treatment costs. Payer-led value assessments and cost-effectiveness analyses heavily influence access and net pricing.
5. When are biosimilars expected to enter the SMA drug market?
Given patent protections, biosimilar entry is anticipated around 2030, though exact timing depends on patent litigation and regulatory pathways.
References
[1] FDA Approved Drugs Database, 2020.
[2] IQVIA, Global Oncology Market Reports, 2023.
[3] Evaluate Pharma, SMA Drug Market Forecasts, 2022.
[4] Roche, Evrysdi Prescribing Information, 2020.
[5] Healthcare Financial Management Association, Payer Strategies in Rare Diseases, 2023.
More… ↓
